$11.94
1.49% yesterday
Nasdaq, Sep 15, 10:00 pm CET
ISIN
US0465131078
Symbol
ATRA

Atara Biotherapeutics Inc Stock price

$11.94
-0.35 2.85% 1M
+4.77 66.53% 6M
-1.37 10.29% YTD
+3.34 38.84% 1Y
-105.56 89.84% 3Y
-379.06 96.95% 5Y
-1,122.56 98.95% 10Y
-254.31 95.52% 20Y
Nasdaq, Closing price Mon, Sep 15 2025
-0.18 1.49%
ISIN
US0465131078
Symbol
ATRA
Industry

Key metrics

Basic
Market capitalization
$83.9m
Enterprise Value
$101.8m
Net debt
$17.9m
Cash
$22.3m
Shares outstanding
7.0m
Valuation (TTM | estimate)
P/E
25.4 | negative
P/S
0.4 | 0.7
EV/Sales
0.5 | 0.8
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-89.2%
Return on Equity
87.8%
ROCE
105.1%
ROIC
210.6%
Debt/Equity
-1.1
Financials (TTM | estimate)
Revenue
$188.7m | $121.4m
EBITDA
$27.8m | $27.9m
EBIT
$23.5m | $-11.2m
Net Income
$5.8m | $-7.5m
Free Cash Flow
$-64.0m
Growth (TTM | estimate)
Revenue
202.4% | -5.9%
EBITDA
117.2% | 138.1%
EBIT
114.0% | 85.6%
Net Income
103.2% | 91.2%
Free Cash Flow
55.1%
Margin (TTM | estimate)
Gross
81.2%
EBITDA
14.8% | 23.0%
EBIT
12.4%
Net
3.1% | -6.2%
Free Cash Flow
-33.9%
More
EPS
$0.5
FCF per Share
$-9.2
Short interest
3.0%
Employees
153
Rev per Employee
$840.0k
Show more

Is Atara Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Atara Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Atara Biotherapeutics Inc forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Atara Biotherapeutics Inc forecast:

Buy
80%
Hold
20%

Financial data from Atara Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
189 189
202% 202%
100%
- Direct Costs 35 35
186% 186%
19%
153 153
207% 207%
81%
- Selling and Administrative Expenses 36 36
13% 13%
19%
- Research and Development Expense 94 94
47% 47%
50%
28 28
117% 117%
15%
- Depreciation and Amortization 4.36 4.36
15% 15%
2%
EBIT (Operating Income) EBIT 23 23
114% 114%
12%
Net Profit 5.80 5.80
103% 103%
3%

In millions USD.

Don't miss a Thing! We will send you all news about Atara Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Atara Biotherapeutics Inc Stock News

Neutral
Business Wire
12 days ago
THOUSAND OAKS, Calif--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Greg Ciongoli will assume the role of Chair of the Board of Directors. Greg Ciongoli is the founder ...
Neutral
Business Wire
about one month ago
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2025 and business updates. Tabelecleucel (tab-cel® or Ebvallo™) ...
Neutral
PRNewsWire
about 2 months ago
First allogeneic T-Cell therapy BLA offers hope to EBV+ PTLD patients who have limited treatment options and lifespan measured in only a few weeks to months following failure of initial treatment EBV+ PTLD is an ultra-rare, acute, and potentially deadly blood malignancy that occurs after hematopoietic cell transplant (HCT) or solid organ transplant (SOT) when T-cell activity is impaired by immu...
More Atara Biotherapeutics Inc News

Company Profile

Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.

Head office United States
CEO Anhco Nguyen
Employees 153
Founded 2012
Website www.atarabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today